AdAlta announces IPO to accelerate development of AD-114
8 July 2016 | By Victoria White, Digital Content Producer
AdAlta is seeking to raise up to AU$10 million to fund clinical studies with its lead compound (AD-114) which shows promise in treating lung fibrosis...